Jicheng Lv, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss 2-year TELIGAN data for telitacicept in IgAN.
||January 13, 2017
Rheumatology Network News Roundup
Author(s)Amy Reyes
In this news roundup, we offer a snapshot of some interesting studies we featured that pose never-ending perplexing questions: When do I switch patients from methotrexate to a biologic? Why didn't my patient report having an adverse reaction? Does vitamin D really protect bones?
Advertisement
In this news roundup, we offer a snapshot of some interesting studies we featured that pose never-ending perplexing questions: Â When do I switch patients from methotrexate to a biologic? Why didn't my patient report having an adverse reaction? Does vitamin D really protect bones?
Advertisement
Related to this article
A PROTECT biomarker analysis shows sparsentan reduced urinary sCD163, BAFF, C5b-9, and IL-6 vs irbesartan through 110 weeks in IgA nephropathy.
Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
Real-world data in 1477 patients on dialysis show tenapanor reduced serum phosphate at 6 months with or without background phosphate binders.
Approval rests on the phase 3 AFFIRM trial, in which 56% of patients reached clinical remission at week 12 vs 30% with placebo.
Jean Elwing, MD, discusses what drove ralinepag's reduction in PAH clinical worsening in ADVANCE Outcomes and where the it could fit if approved.
Jean Elwing, MD, discusses a CHEST 2026 subgroup analysis showing ralinepag reduces clinical worsening in PAH even among patients with low-risk criteria.
Participants described earlier phenotyping, closer tracking of steroid exposure, and recognizing gradual gains on biologic therapy.
Advertisement
Advertisement
Trending on HCPLive
1
Ralinepag's Benefit Spans Broad PAH Population, With Jean Elwing, MD
2
RAINIER: Povetacicept Cuts Proteinuria, Gd-IgA1 in IgA Nephropathy
3
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
4
IMAgINATION: Sefaxersen Meets Phase 3 Proteinuria Endpoint in IgA Nephropathy
5